About ChromaCode
ChromaCode is a Healthcare company based in Carlsbad (United States) founded in 2012. Digital molecular biology analytics are developed for disease management. ChromaCode has raised $95.02 million across 8 funding rounds from investors including Caltech, Shimadzu Corporation and Global Brain. The company has 46 employees. Its chief executive, as recorded, is Paul Flook. ChromaCode offers products and services including HDPCR Technology, ChromaCode Cloud, and Reagent Kits. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is CHROMACODE, INC. Its competitors include NeuMoDx, Biofire Diagnostics and Kryptos Biotechnologies; 3 of its 3 listed competitors have raised funding.
Company details
ChromaCode was founded in 2012 and is headquartered in Carlsbad, United States. Operations focus on the biotechnology sector, where digital molecular biology analytics are provided for disease management. A proprietary platform is utilized alongside existing qPCR instruments to expand multiplexing capabilities. Cloud-based software and assay design are employed to support these functions, enabling integration with standard laboratory equipment.
- Headquarters Carlsbad, United States
- Employees 46
- SectorsHealthcare
- Website chromacode.com
- Social LinkedIn X Facebook
- Legal Name Chromacode, Inc.
- Total Equity Funding$95.02M (USD)
in 8 rounds
- Latest Funding Round$3.85M (USD), Series C
Jan 2025
- InvestorsCaltech
& 9 more
- Employee Count46
Products & Services of ChromaCode
ChromaCode offers a comprehensive portfolio of products and services, including HDPCR Technology, ChromaCode Cloud, and Reagent Kits.
Multiplexing platform for DNA and RNA variants in oncology testing.
Cloud-based tool for data analysis and assay deployment in labs.
Kits for cost-effective genomic workflows in clinical settings.
Funding Insights of ChromaCode
ChromaCode has successfully raised a total of $95.02M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $3.85 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $95.02M
- Total Rounds 8
- Last Round Series C — $3.85M
- First Round $2.5M
(Jul 2015)
- Investors Count 10
All 8 funding rounds of ChromaCode with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $3.85M | Series C | – | – | – |
| Jun 2023 | Series C | – | Shimadzu Corporation, Global Brain | – | |
| Dec 2020 | $38.64M | Series C | – | Northpond Ventures | |
| May 2020 | $10M | Series C | – | Adjuvant Capital | – |
| Dec 2019 | $28M | Series C | – | Northpond Ventures | |
| Apr 2019 | $1.75M | Debt – Conventional | – | – | – |
| Apr 2017 | $12.02M | Series B | – | New Enterprise Associates | |
| Jul 2015 | $2.5M | Series A | – | – |
10 investors in total: 10 institutional.
Investors in ChromaCode
ChromaCode has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Caltech, Shimadzu Corporation and Global Brain.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global Brain is recognized as a venture capital firm supporting startups. | globalbrains.com | Shibuya, Japan | ||
Venture capital firm investing in life sciences & tech sectors | npv.vc | Cambridge, United States | ||
Growth & expansion stage VC firm invesing in the US | moorevp.com | Encinitas, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
US focused VC investment company | okapivc.com | Newport Beach, United States | ||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Venture capital is deployed for global health technology innovations. | adjuvantcapital.com | New York City, USA | ||
Medical imaging systems, industrial machinery, and analytical instruments are provided. | 1875 | shimadzu.com | Tokyo, Japan | |
Windham Capital Partners is focused on HealthTech venture investments. | windhamvp.com | New York, United States | ||
Higher education and research in science and engineering are offered. | 1891 | caltech.edu | United States |
Investor details for ChromaCode
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ChromaCode
25 people are tracked at ChromaCode (5 in leadership, 10 in board & advisors, 10 in team); the tracked headcount is 46.
| Name | Role | Group |
|---|---|---|
Paul Flook | CEO | Leadership |
Aditya Rajagopal | Co-Founder & Chief Technical Officer | Leadership |
Jerrod Schwartz | VP, Advanced Technology Group | Leadership |
Lucien Jacky | Vice President Research And Development | Leadership |
Nathaniel Clark | Director Of Software Engineering | Leadership |
Carol Gallagher | Director | Board & advisors |
Gregory Tsongalis | Scientific Advisor | Board & advisors |
Andrea Ferreria-Gonzalez | Scientific Advisor | Board & advisors |
Yaser Abu-Mostafa | Advisor | Board & advisors |
Michael Frumkin | Advisor | Board & advisors |
Jenny Yip | Director | Board & advisors |
Pat Smerkers | Director | Board & advisors |
Joseph S. Bailes | Scientific Advisor | Board & advisors |
Kevin C. O’Boyle | Director | Board & advisors |
Justin Klein | Director | Board & advisors |
Paige Berroteran | Research Associate II | Assay Development | Team |
Janine Wiese | Clinical Affairs Manager | Team |
Juan Enciso | Senior Research Associate | Team |
Kristen Verespy | Senior Human Resources Manager | Team |
Kristen Culp | Manager Of Customer Excellence | Team |
5 more people are available in the full profile.
Complete people profiles for ChromaCode
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ChromaCode
3 dated milestones of ChromaCode across 13 years, from founding to its latest funding, stage changes and deals.
- Founded ChromaCode is founded.
- Funding First funding round of $2.5M.
- Funding Latest funding round, Series C, of $3.8M.
Competitors of ChromaCode
ChromaCode has 3 listed competitors in our database, 3 of them funded. They include NeuMoDx, Biofire Diagnostics and Kryptos Biotechnologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neumodx.com | 2012 | Ann Arbor, United States | $66.04M | 125 | Developer of a platform for low cost molecular testing | |
| biofiredx.com | 1990 | Salt Lake, United States | $84M | 8 | Molecular diagnostic solutions for genetic condition detection are provided. | |
| kryptosbio.com | 2017 | Hayward, United States | $12.7M | Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology. |
Detailed competitors of ChromaCode
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as ChromaCode (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chromacode
Complete news archive for ChromaCode
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ChromaCode
ChromaCode was founded in 2012 and raised its 1st funding round 3 years after it was founded.
ChromaCode is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Paul Flook is the CEO of ChromaCode, as recorded in our data.
ChromaCode is a funded company, having raised a total of $95.02M across 8 funding rounds to date. The company's 1st funding round was a Series A of $2.5M, raised on Jul 2015.
ChromaCode has 46 employees.
ChromaCode was founded in 2012 and is headquartered in Carlsbad, United States. Operations focus on the biotechnology sector, where digital molecular biology analytics are provided for disease management. A proprietary platform is utilized alongside existing qPCR instruments to expand multiplexing capabilities. Cloud-based software and assay design are employed to support these functions, enabling integration with standard laboratory equipment.
ChromaCode's top competitors include NeuMoDx, Kryptos Biotechnologies and Biofire Diagnostics.
ChromaCode offers HDPCR Technology, ChromaCode Cloud, and Reagent Kits.
ChromaCode has 10 investors. Key investors include Caltech, Shimadzu Corporation, Global Brain, Northpond Ventures, and Windham Capital Partners.
ChromaCode operates through Chromacode, Inc..